% of pts treated w/ everolimus who require a dose adjustment?
What proportion of your patients receiving everolimus require dose adjustments for toxicity?
Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9. Abstract
Burris HA et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 2013;119(10):1908-15. Abstract
Campone M et al. Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2- advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Curr Med Res Opin 2013;[Epub ahead of print]. Abstract
Paplomata E et al. Everolimus: Side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 2013;140(3):453-62. Abstract
Villarreal-Garza C et al. mTOR inhibitors in the management of hormone receptor-positive breast cancer: The latest evidence and future directions. Ann Oncol 2012; 23(10):2526-35. Abstract